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The cellular responses to tumor cells are mediated by a variety of cell types,
such as T cells, NK or lymphokine-activated killer (LAK)' cells, and macrophages
(1-7). T cells possess the distinctive features ofbeing clonally distributed and of
recognizingtheantigen on thetarget cell membrane inassociation with molecules
coded for by genes of the MHC. Three major T lymphocyte subsets (helper,
cytotoxic, and suppressor) participate in the response to malignant cells (1-3).
The firsttwo cell types may exerta function that is beneficial to the host, whereas
suppressor T cells may facilitate tumor growth. The different Tcell subsets can
be recognized through the expression ofdistinctive surface markers and can also
be tested in a variety of experimental systems. Nevertheless, there has been so
far considerable difficulty in elucidating the types ofcell interactions that occur
during the response to cancer cells. Lack ofknowledge in the field has impeded
clarification ofthe mechanisms that lead to a failure oftumor rejection. This has
been particularly true for the studies on human tumors, where only in vitro
methods could be used. In addition, the prevalent use of peripheral blood as a
potential source of tumor-specific T lymphocytes may have contributed to the
difficulties encountered in these studies (as discussed in 8-10). In the peripheral
blood, Tcells with specificity for tumor antigens may be far too diluted, or else
theiractivity may be masked by that ofpossibly more powerful cytotoxic effector
cells such as LAK or NK cells.
In the present investigation, we have explored the possibility that lymph nodes
drainingthe tumor site from patients with cancer ofthe larynx or ofthe bladder
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could contain tumor-specific T lymphocytes. These experiments were in part
suggested by previous observations that these lymph nodes comprise T cells with
particular and somewhat unusual surface phenotype (11).
We show that invaded lymph nodes contain T lymphocytes that can be induced
to proliferate specifically in response to the patients' malignant cells. A positive
response requires, however, that two basic conditions are met, namely that the
cultures are supplemented with IL-1 and that a subset of suppressor T cells with
a distinctive surface phenotype is removed from the suspensions.
Materials and Methods
LymphNodes and Neoplastic Tissues.
￿
Pelvic lymph nodes from 18 patients with transi-
tional cell carcinoma of the bladder and cervical lymph nodes from 12 patients with spino-
cellular carcinoma of the larynx were obtained after informed consent. Each lymph node
was divided into two parts for histopathologic evaluation and for in vitro studies. Frag-
ments of tumor tissues were obtained from individual patients under sterile conditions.
Antibodies and Surface Marker Analysis.
￿
Anti-T cell mAbs OKT3, OKT4, OKT8 (12)
were obtained from Ortho Diagnostic Systems, Milano, Italy. The OKM1 mAb, that
recognizes the a chain of the C3bi receptor on monocytes, granulocytes, T cells, and NK
cells (13), was also purchased from Ortho Diagnostic Systems. The monocyte-specific Leu-
M3 mAb (14) and Leu-1 Ib mAb, which detects the receptor for the Fc portion of IgG on
granulocytes and NK cells (15), were purchased from Becton Dickinson Laboratory
Systems, Milano, Italy. The B cell-specific B1 mAb (16) was obtained from Coulter-
Kontron, Milano, Italy. HNK-1 clone, originally raised by Abo and Balch (17, 18), which
produces the Leu-7 mAb, was obtained from the American Type Culture Collection,
Rockville, MD. The mAb, which detects subpopulations of NK cells and of T cells, was
purified from ascites fluid by filtration on a Ultrogel AcA 34 column. An mAb that reacts
with the IL-2 receptor (anti-Tac) (19) was kindly provided by Dr. T. A. Waldmann,
National Institutes of Health, Bethesda, MD. PTF 29/12 mAb, an anti-HLA-DR nonpoly-
morphic determinant (20), and 22.1 mAb, an anti-HLA-A,B,C monomorphic antigen
(21), were generous gifts of Dr. G. Damiani, University of Genova.
F(ab')2 fragments of affinity-purified goat anti-mouse Ig (GAMIg) and their FITC-
conjugated forms were prepared as previously described (22), and used for cell separation
and indirect immunofluorescence analysis, respectively. The polyclonal rabbit anti-human
IL-1 antiserum was purchased from Genzyme, Boston, MA.
Surface marker analysis of lymph node cells, or of the cell lines thereof, was carried
out by conventional fluorescence microscopy, as described (22). For the quantitative
evaluation of Tac antigen expression by cultured lymph node cells, a cytofluorographic
analysis was carried out with a FACS (Becton Dickinson Laboratory Systems). 106 cells
were treated at 4 °C for 30 min with anti-Tac mAb (ascites, 1 :1,000 final dilution), washed
in HBSS, and incubated with F(ab')2 fragments of GAMIg for additional 30 min. An
aliquot of freshly isolated cells, stained as above, was fixed in a 1 % formaldehyde solution
in HBSS, FACS analyzed after 3 d, and compared with cultured cells. Controls included
cellstreated with an unrelated monoclonal Ig ofthe same isotype. The data were expressed
as a histogram in which the fluorescence intensity (log) was plotted on the abscissa against
the relative number of cells on the ordinate. In parallel, volume-distribution histograms,
based on forward light scatter, were plotted for each sample.
Cell Separation Procedures.
￿
Lymph node fragments were gently dissociated to obtain
single-cell suspensions. Mononuclear cells were separated on Ficoll-Hypaque density
gradients.
Cells that expressed the Leu-7 marker were fractionated by a direct rosetting technique
with ox red cellscoated with the purified Leu-7 mAb, as described (23). Cells bearing the
OKM 1 determinant were separated by indirect rosettes, according to Egeland and Lea
(24). Briefly, 2 x 107 cells were resuspended in 400 Ed of a 1 :10 dilution of the OKM 1
mAb in HBSS and kept at 4°C for 30 min. After two washes with cold HBSS, cells wereCOZZOLINO ET AL.
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incubated with a 1 % suspension of ox red cells coated with F(ab')2 fragments of GAMIg
at 37'C for 1 h. Rosetting cells were then separated by Ficoll-Hypaque density gradients,
as described (23). Red cells were lysed by incubating at 4°C for 10 min with a 0.83%
NH4CI solution.
Peripheral blood mononuclear cells were fractionated into T cells and non-T cells by
rosetting with neuraminidase (Sigma Chemical Co., St. Louis, MO)-treated sheep red
blood cells, as described (23). Non-T cells were irradiated (3,000 rad) and used as
stimulator cells against autologous T cells in a mixed lymphocyte reaction. In all of the
above experiments, the rosette-enriched fractions contained >94% rosetting cells.
To isolate tumor cells, fragments of - 1 cm3 were cut from the tumor mass and
mechanically dissociated in the presence of0.2 mg/mldeoxyribonuclease (Sigma Chemical
Co.). To remove large cell aggregates, the suspensions were purified on Ficoll-Hypaque
gradients. Tumor cells were separated from tumor-infiltrating lymphocytes by Percoll
density gradients, as described by Kedar et al . (25). Briefly, 3 X 107 cells were layered
onto a discontinuous gradient of 25, 15, and 10% Percoll in HBSS and centrifuged for 7
min at 25 g. The pellet, enriched in tumor cells, was recovered and washed twice;
cytocentrifuge smears were prepared to assess the purity of the suspension, which always
exceeded 95%. Aliquots of tumor cells were frozen in 90% FCS/10% DMSO (Sigma
Chemical Co.) over liquid nitrogen.
Cell Cultures.
￿
To test the response of T lymphocytes to tumor cells, various numbers
of isolated lymph node cells or fractions thereof were cocultured with irradiated (5,000
rad) autologous or allogeneic tumor cell suspensions in flat-bottom microtiter plates in a
total volume of 0.2 ml of RPMI 1640 (Flow Laboratories, Milano, Italy) at 37 ° C in a
humidified atmosphere with 5% C02. RPMI 1640 was supplemented with 10% FCS
(Gibco, Mascia Brunelli, Milano, Italy), 2 MM L-glutamine (Sigma Chemical Co.), 100
Ag/ml streptomycin, 100 IU/ml penicillin (RPMI-FCS). Unless otherwise stated, the cells
were cultured for 6 d.
For the autologous mixed lymphocyte reactions, lymph node or peripheral blood cells
(or fractions thereof) were cultured with irradiated (3,000 rad) peripheral blood non-T
cells, as stimulator cells. 2.5 X 104 responder cells were cultured with an equal number of
stimulator cells, using the same conditions as above. Cultures were pulsed with 0.5 ACi of
[3H]TdR (sp act 25 Ci/mmol ; Amersham, Prodotti Gianni, Milano, Italy), harvested 18 h
later, and the radioactivity was determined in a liquid scintillation counter (Beckman
Analytical, Milano, Italy).
Statistical evaluation of data was performed by Student's t test.
Lymph node cells were stimulated with 1 ug/ml PHA (PHA-P; Wellcome, Pomezia,
Italy) or cultured with rIL-2 (25 U/ml), kindly donated by Biogen S.A., Geneva, Switzer-
land, with purified IL-1 (Genzyme), or human rIL-1-,Q, a generous gift of Biogen S.A.
(0.5-2 U/ml). These experiments were generally carried out by culturing 2.5 X 104
cells/well in 96-well plates. Cell proliferation was assessed as above. When larger cell
quantities were needed, the cultures were set up in 24-well plates, at 106 cells/ml, in the
same conditions as above, or, when indicated, in the presence of rIL-2 or of purified IL-1 .
To obtain continuous T cell lines, 2.5 X 105 OKMI -, Leu-7- cells from metastatic
lymph nodes were cocultured in 24-well plates with 2 X 10' irradiated autologous tumor
cells in 1 ml of RPMI-FCS, containing 2 U of purified IL-1 . After 6 d, the supernatant
was removed and replaced with fresh medium containing 25 U/ml rIL-2; at this time,
additional tumor cells were added. This procedure was repeated every third day.
To test the proliferative activity of the cell line, 2 .5 X 104 cells were cultured for 3 d
in the above conditions, with autologous or allogeneic irradiated tumor cells and/or rIL-
2. When indicated, the cultures were set up in the presence of PTF 29/12 anti-HLA-DR
antibody or 22.1 anti-HLA-A,B,C antibody, 1 :1,000 final dilution of ascites fluids.
IL-2 Assay.
￿
4 X 103 murine IL-2-dependent CTLL-2 cells in 100 Al of RPMI-FCS
containing 2.5 X 10-5 M 2-ME were incubated with 100 Al of various dilutions of test
supernatants, in triplicate, at 37°C. After 24 h, 0.5 ACi of [3H]TdR were added, and
incubation was continued for another 4 h. The incorporated radioactivity was assayed as306
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described above. The IL-2 U/ml were defined as the reciprocal ofthe supernatant dilution
that induced 50% of maximal proliferation of CTLL-2 cells.
IL-1 Assay.
￿
IL-1 activity was tested by the thymocyte costimulation assay, as described
(23). Briefly, thymuses were surgically removed from C3H/Hej mice; single-cell suspen-
sions were obtained and thymocytes (1 .5 X 106 cells/well) were cultured in triplicate for
72 h in 96-well, flat-bottomed plates, in the presence of 1 ug/ml PHA alone, or PHA plus
serial dilutions of the supernatants to be tested. Subsequently, the cells were pulsed with
1 jiCi of [sH]TdR for 8 h, harvested, and counted. 1 U of IL-1 was defined as the amount
of supernatant capable of doubling the [sH]TdR incorporation by 1 .5 X 106 stimulated
thymocytes.
Cytotoxicity Assay.
￿
Cytotoxic activity was measured in a conventional 4-h assay against
"Cr-labeled cells, as described (23). Briefly, 2 X 106 viable (>80%) tumor cells, or K562
cells, were resuspended in 0.5 ml of RPMI-FCS and incubated with 300 Al of Nat"CrO4
(sp act 200-500 Ci/mmol; NEN, Du Pont Italia, Firenze, Italy) at 37 ° C for 60 min. The
cells were washed three times, kept for an additional 60 min at 37'C, and subsequently
washed twice. E/T ratios of 30:1, 10:1, 1:1 were selected. E/T mixtures were incubated
for 4 h, were centrifufed, the supernatants were recovered, and their radioactivity was
determined. Maximal 'Cr release was determined by lysing the labeled cells with 0.1 N
HCI . The percent specific "Cr release was calculated as: 100 X [(release in presence of
effector cells) - (release from labeled cells)]/[(release in presence of HCI) - (release from
labeled cells)].
Cold-target inhibition studies were performed by first incubating the effector cells with
unlabeled target cells (effector/cold target ratio of 20:1) for 1 h at 37 ° C, then with "Cr-
labeled cells. The assay was then performed as above.
Results
Response ofLymph Node Cells to Autologous Malignant Cells.
￿
In an initial series
of experiments, lymphocytes from lymph nodes with and without metastases
were tested for their ability to proliferate in response to autologous malignant
cells obtained from the primary tumor lesion (mixed lymphocyte-tumor culture
[MLTC]). Lymph nodes were subdivided as having or not having metastases
according to conventional histopathology. In these experiments, a significant
proliferative response was never observed, although a number of variables, such
as cell concentration, stimulator/responder cell ratio, duration of coculture
period, were tried . Lymph node cells were also studied for their cytotoxic activity
against "Cr-labeled autologous neoplastic cells. Again, a cytotoxic response was
never obtained (data not shown).
In principle, the failure to observe a response could be related to any of the
following, albeit not mutually exclusive, conditions: (a) absence of a tumor
antigen(s)-specific lymphocyte population; (b) requirement for exogenous lym-
phokines; (c) influence of suppressor mechanisms. These possibilities were inves-
tigated as follows.
Cells from both invaded and noninvaded nodes were cultured in the presence
of exogenous IL-2, with or without autologous tumor cells. The cells gave a
significant response to IL-2, which was not modified by the presence of malignant
cells (Table I). The response induced by exogenous IL-2 was not unexpected,
because a number of cells stained strongly for Tac antigen (see below and
Cozzolinci et al. [I I]).
Previously, we have shown that metastatic lymph nodes contain a proportion
(--20%) of cells that simultaneously express the T3, T8, OKM1, and Leu-7
markers (11). These cells are also present in noninvaded lymph nodes, albeit inCOZZOLINO ET AL.
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TABLE I
Proliferative Response ofCellsfrom Regional Lymph Nodes to rIL-2
['H]TdR incorporation*
' 2.5 x 104 lymph node cells were cultured for 6 d in the presence or absence of 250 irradiated (5,000 tad) autologous tumor cells.
Values are expressed as mean t SD of triplicate cultures.
x Data from 3 representative experiments outof 15 performed (8 with bladder, 7 with larynx cancer lymph nodes)are reported.
f Data from three representative experiments, out of nine performed (five with bladder, four with larynx cancer lymph nodes), are
reported.
1 rIL-2 was used at 25 U/ml final dilution.
TABLE 11
Surface Phenotypes of Cellsfrom Metastatic and
NonmetastaticLymph Nodes
Mean ±SD ofpooled data.Lymph nodes from six patients with carcinoma
of the bladder and four patients with carcinoma of the larynx were
analyzed.
much lower proportions. These data have been confirmed here (Table 11 and
results of double-staining experiments not shown) . Because a number ofrecent
observations have indicated that a subset of human suppressor T cells have a
T3+, T8+, OKM1 +, Leu-7' surface phenotype (26, 27), the possibility existed
that cells with this phenotype could suppress the in vitro response to malignant
cells. Cells from metastatic lymph nodes were depleted of OKM1 +, Leu-7+ cells
(OKM1 -, Leu-7- cells) and tested in MLTC. The results are summarized in
Table 111. OKM1 -, Leu-7- cells were capable of a significant response against
malignant cells, provided that exogenous IL-2 was present, i.e., cells cultured
with IL-2 and tumor cells proliferated more vigorously than cells cultured with
IL-2 alone. Readdition of graded numbers of OKM1', Leu-7+ cells (up to the
proportions occurring in the unfractionated lymph node) inhibited the response
to tumor cells in the presence of IL-2, but did not affect the cell proliferation
induced by exogenous IL-2. Taken together, these experiments show that
Marker
T3
B1
Percentage of
Metastatic nodes
(n = 11)
65.5 t 11 .3
18.7±3.9
positive cells from:
Nonmetastatic nodes
(n = 18)
54.0 ± 13.9
29.4±11.2
Leu-M3 9.1 ± 3.7 7.1 ± 2.9
T4 45.2± 10.1 37.2±9.5
T8 39.5 f 11 .5 18.5 ± 6.9
OKM1 27.8 ± 15.3 9.8 ± 3.4
Leu-11 4.9 ± 1.8 6.2 ± 2.7
Leu-7 15.3 ± 7.2 6.9 t 5.7
HLA-DR 38.9 ± 13 .7 42.5 ± 10.2
Tac 21 .1±8.2 11 .8±4.2
Stimulus
Exp. 1
Invaded nodes
Exp. 2 Exp. 3
rpm
Exp. I
Noninvaded nodesi
Exp. 2 Exp. 3
Medium alone 250 t 62 340 t 87 246 t 43 405 t 84 502 t 48 498 t 85
Autologous tumor cells 484 t 58 457 t 75 358 t 96 608 t 101 701 t 113 655 t 93
rIL-21 5,235 t 489 6,875 t 997 4,819 t 898 4,543 t 756 3,254 t 549 2,917 t 318
Autologous tumor cells + rIL-21 5,847 t 901 6,102 t 814 5,104 t 478 3,968 t 667 3,718 t 779 3,195 t 555308
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TABLE III
Proliferative Response ofFractionated Cellsfrom Invaded LymphNodes
Num-
bers of
￿
['H]TdR incorporation by
Three representative experiments, two with larynx carcinoma and one with bladder carcinoma
lymph node cells, out of six performed, are shown. Mean ± SD of triplicate cultures.
* 250 irradiated (5,000 rad) tumorcells were added.
$ rIL-2 was added at 25 U/ml final dilution .
invaded lymph nodes contain a cell population capable of a proliferative response
to tumor cells, which can be detected following removal of suppressor cells and
addition of exogenous IL-2 .
Cells from lymph node with no metastases failed to respond in MLTC even
after removal of the OKM 1'}, Leu-7+ cells, perhaps suggesting that cells with
specificity for malignant cells were absent (data not shown).
Next we investigated whether or not cells from invaded lymph nodes were
restricted to respond to autologous cells or could also respond to allogeneic cells.
As shown in Table IV, the proliferation of lymph node cells did not increase
above the values induced by IL-2 after addition of allogeneic malignant cells.
Failure to respond to allogeneic tumor cells was independent of the histologic
type of the tumor cells used for stimulation.
Thepossibility that OKM1-, Leu-7- cellscould respond in an autologous MLR
was investigated by coculturing these cellswith autologous peripheral blood non-
T cells. A significant response was never observed, even in the presence of
exogenous IL-2, thus indicating that invaded lymph nodes contain a very limited
number (if any) of T cells reacting in an autologous MLR. These observations
exclude the hypothesis that the antigen(s) recognized by OKM1 -, Leu-7- cells
on malignant cells is represented only by autologous MHC-encoded determi-
nants.
Expression of IL-2 Receptors and Failure of Lymph Node Cells to Produce IL-2 in
Autologous MLTC. The problem of whether or not coculture with autologous
tumor cells could induce IL-2 receptor expression by OKM1-, Leu-7- cells was
next addressed. OKM1-, Leu-7- cells were cocultured with malignant cells for
3 d and subsequently stained for Tac antigen expression . After coculture with
autologous tumor cells, a high proportion of OKM 1-, Leu-7- cells expressed
Tac antigen (Fig. IA). Furthermore, the intensity of staining of the single cells
Stimulus OKM1+,
Leu-7+
cells
added
OKM1-, Leu-7- cells
Exp. I Exp. 2 Exp. 3
cpm
Medium alone - 489 ± 27 327 ± 41 521 ± 49
Autologous tumorcells* - 544 ± 46 389 ± 38 589 ± 23
rIL-2t - 7,249 ± 825 8,544 t 1,154 7,986 ± 1,084
Autologous tumor cells + rIL-2*4 - 17,589 t 1,057 18,911 ± 2,185 17,925 ± 1,825
8.0 x 103 8,648 t 1,115 8,725 ± 985 9,187 t 1,101
4.0 x 103 10,459 ± 988 11,427 ± 1,529 12,185 t 1,206
2.0 x 103 13,728 ± 1,224 12,689 ± 1,619 13,888 ± 1,526
1.0 x 103 15,644 ± 1,229 16,704 t 1,815 17,119 ± 1,614COZZOLINO ET AL.
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TABLE IV
Proliferative Response ofOKMI -, Leu-7- Cellsfrom Metastatic
Lymph Nodes to Different Cell Types
Three representative experiments, two with larynx carcinoma and one with bladder carcinoma
lymph node cells, out of six performed, are shown. 2.5 X 10' fractionated cells were cultured for
6 h. Mean ± SD of triplicate cultures.
* Fractionated lymph node cells from a larynx cancer patient.
Fractionated lymph node cells from a urinary bladder cancer patient.
§rIL-2 was addedat 25 U/ml final dilution.
9 250 irradiated (5,000 rad) autologous or allogeneic tumorcells were added.
' 2.5 X 10' irradiated (3,000 rad) autologous peripheral blood non-T cells were added.
increased significantly, ascompared to thatofTac'cellspresent in thesuspension
before culture (6-9%) (Fig. I A). Interestingly, the cells that expressed Tac
antigen after 3 d belonged to either the T3+, T4+ or to the T3+, T8+ cell subset
(data notshown). By contrast, in thesuspensions cultured alone or with allogeneic
tumor cells there was no increase in the proportion of Tac* cells (Fig. 1B).
OKM1-, Leu-7- cells did not increase in size when cultured with malignant cells.
These findings suggest that the encounter with malignant cells provided a
sufficient signal for IL-2 receptorexpression, but that the cells couldnot proceed
further in their cycle, probably owing to the absence of IL-2.
To study whether or not the responding cells could produce IL-2 in the
MLTC, OKMI -, Leu-7- cells were cultured with malignant cells. IL-2 was
measured in the culture supernatants after 3 d. Coculture with either autologous
or allogeneic tumor cells failed to induce significant IL-2 production in four
consecutive experiments. By contrast, PHA stimulation of the same OKM1 -,
Leu-7- cells caused abundant IL-2 release (1-2 U/ml per 106 cells).
Characterization of Short-term Lines Derived from MLTC.
￿
These experiments
were intended to investigate further the fine specificity ofOKM1 -, Leu-7- cells
and to explore the possibility ofobtaining cells with cytotoxic properties against
tumor cells. As stated above, no cytolytic cells were detected in freshly prepared
suspensions.
OKMI -, Leu-7- cells were stimulated with IL-2 and autologous malignant
cells, and subsequently expanded by further addition of both IL-2 and malignant
cells. With this method, five cell lines were obtained. They comprised cells with
either T3+, T8+ or T3', T4+ phenotype, the former being predominant in four
Stimulus
['H]TdR incorporation by OKM1 -,
Exp. I* Exp. 2*
Leu-7-cells
Exp. 3$
CPm
Medium alone 389 ± 54 527 ± 79 287 ± 44
rlL-2§ 6,874 ± 1,657 8,534 ± 1,421 7,741 ± 1,469
Allogeneic tumorcells + rIL-2§,"
Bladder tumor I 5,352 ± 538 9,719 ± 1,035 7,397 ± 987
Bladder tumor II 6,835 ± 895 9,562 ± 1,859 8,485 ± 1,024
Larynx tumor I 5,987 ± 1,038 9,001 ± 1,215 6,984 ± 954
Larynx tumor II 7,021 ±973 8,528 ± 938 7,427 ± 1,045
Autologous tumor cells + rIL-2§,1 18,348 ± 2,126 16,578 ± 1,741 15,291 ± 1,003
Autologous non-T cells' 415±171 398±101 361±87
Autologous non-T cells + rIL-2§'' 7,415 ±526 8,144 ± 619 6,867 ± 48931 0
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B
fluorescence intensity
￿
cell volume
FIGURE 1.
￿
FACS analysis of Tac antigen expression by cells from metastatic lymph node.
Isolated OKM1-, Leu-7- cells were cultured for 72 h in thepresence (line 2) or absence (line
3) of malignantcells and stained with anti-Tac mAb. An aliquot of freshly isolated OKM1-,
Leu-7-cells from the same cell suspension wasstained, formaldehyde-fixed, andanalyzed after
3 d in comparison with cultured cells (line 4). Coculture with autologous (A), but not with
allogeneic (B), tumorcellsinducedTac antigen expression. In this experiment, representative
of five performed, the cells had, at day 0, the following surface phenotype: T3', 71 .3%; T4',
47 .5%; T8', 21 .8; HLA-DR', 26.3%; Tac', 7.8%. After 3 d, the phenotype was basically
unmodified, except that Tac' cells were 46.3%. Line 1 shows control with FITC-conjugated
goat anti-mouse antibodies (GAMIg) alone. Volume distribution histograms of the same cell
populations show no differences in cell size.
of them. The availability of a cell line (FD) that contained predominantly T3+,
T8' cells (i.e., with a cytotoxic cell surface phenotype) allowed to investigate
further the question of whether or not a cytotoxic activity could be generated in
the system. The T3+, T8' cell line proliferated specifically in response to
autologous but not allogeneic tumor cells in the presence of IL-2 (Table V).
Furthermore, the specific proliferative response was abrogated by addition ofan
anti-HLA-A,B,C mAband notbyanti-HLA-DR mAb. This findingshows restric-
tion ofthe cells for class I antigens. Interestingly, the treatment with anti-HLA-
A,B,C mAb failed to inhibit the response induced by IL-2 alone. The FD cell
line showed a weak although definite cytotoxic response against autologous
tumorcells. No significant lytic activity wasever observed against three unrelated
tumor cells nor to K562 cell line (Fig. 2). The latter control was included to
ascertain whether or not the cells possessed an NK-like activity. Specificity for
autologous tumor cells was confirmed by cold-target inhibition assays, where
autologous but not allogeneic malignant cells inhibited the lytic reaction (Fig. 2).
OKMI -, Leu-7- Cells Can Be Induced to Mount an MLTC by Addition of
IL-1 . These experiments were intended to investigate the role possibly played
by IL-1 in the MLTC response of OKM1-, Leu-7- cells. In the absence of IL-1-_U
X
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TABLE V
Proliferative Activity ofCell Line FDfrom Metastatic Lymph Node
OKMI-, Leu-7- Cells
Line FD was raised from a larynx cancer patient and comprised 70-80% cells
with a T3+, T8+ surface phenotype. Theremainingcells were T3*, T4*.
* Mean t SD of triplicate cultures. 2.5 X 10'cells were cultured for 3 d.
$When indicated, 250 irradiated (5,000 rad) autologous or allogeneic (I from a
larynx cancer, 11 from a urinary bladder cancer) tumor cells and/or HL-2, 25
U/ml finaldilution, were added.
$ Ascites, 1:1,000 final dilution.
E/T CELL RATIO
B
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FIGURE 2.
￿
Cytotoxic activity of a cell line (FD) derived from OKMI -, Leu-7- cells isolated
from a metastatic lymph node of a larynx cancer patient. Cells were initially plated in the
presence of IL-I (2 U/ml) and autologous tumor cells, and subsequently expanded in IL-2-
containing medium. After 18 d, the cells were tested against "Cr-labeled autologous tumor
cells (/), allogeneic larynx cancer cells (O, A), allogeneic bladder cancer cells (O), and K562
cells(") (A). Preincubation with unlabeled autologous (/), but notallogeneic (O, A, 0), target
cellscaused a marked reduction in the cytotoxic activity against autologous tumor cells (B).
Stimulust ['H]TdR incorpo-
ration*
cpm
Medium alone 1,146 ± 386
Autologous tumor cells 1,427 ± 456
Allogeneic tumor cells I 1,526 ± 712
Allogeneic tumorcells II 1,289 ± 279
rIL-2 13,784 ± 1,126
Autologous tumor cells+ rIL-2 21,025 ± 2,284
Autologous tumor cells + HL-2 + anti-HLA-A,B,Cf 11,287 ± 995
Autologous tumor cells+ rIL-2 + anti-HLA-DR§ 19,857 ± 2,133
Allogeneic tumor cells I + rIL-2 12,825 ± 956
Allogeneic tumor cells II + rIL-2 14,275 ± 1,829312
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TABLE VI
Proliferative Response and IL-2 Production by OKM1 -, Leu-7- Cells from Metastatic Lymph
Nodes in the Presence ofIL-1
Stimulus
￿
[sH]TdR incorporation
IL-2
production4
Data from two representative experiments (one with larynx and one with bladder cancer lymph node cells), out ofeight performed,
are shown.
# Mean t SD oftriplicate cultures. 2.5 X 10° OKMt-, Leu-7- cells from metastatic lymph nodes were cultured for 6 d.
f OKMI-, Leu-7- cells were cultured at a cell concentration of 106 cells/ml. IL-2 activity was measured in the supernatants by the
CTLL-2 proliferation assay.
* When indicated, polyclonal rabbit anti-human IL-1 antibodies were added at 1 :100 final dilution.
1 Affinity-purified human monocyte IL-1 was added. Superimposable results were obtained using human HL-1-0.
When indicated, 250 irradiated (5,000 rad) tumor cells were added.
rich accessory cell supernatants, antigen- or mitogen-activated T cells express
IL-2 receptors, but fail to produce IL-2 (28-30). It was therefore possible that
the limiting factor for the cells that did not respond in MLTC was represented
by the insufficient supply of IL-1. This was also confirmed by the finding that
supernatants of 10 different autologous MLTC did not contain detectable IL-1,
as assessed in the thymocyte costimulation assay (data not shown). The absence
of IL-1 would have in turn impeded both IL-2 production and cell proliferation.
To test this hypothesis, OKMl-, Leu-7- cells were cultured with different
dilutions of purified or recombinant IL-1, in the presence of malignant cells.
Representative experiments with optimal doses of IL-1 are shown in Table VI.
Addition of IL-1 resulted in cell proliferation, even in the absence of exogenous
IL-2. When IL-1 was added, the cells also produced IL-2. Some proliferation
was also induced by IL-1 alone, albeit not comparable to that induced by
malignant cellsplus IL-1. This phenomenon was notattributable tothe mitogenic
effect of IL-1, possibly contaminated by endotoxin, as T cells purified from
peripheral blood were not induced to proliferate by the same IL-1 preparations,
under the same experimental conditions (data not shown). Furthermore, stimu-
lation of lymph node cells by IL-1 was inhibitable in the presence of anti-IL-1
antibodies (Table VI). Rather, lymph node cell proliferation in the absence of
malignant cells could be related to the presence of a number of cells already
IL-11
U/ml
Autologous
tumor cells
Anti-IL:1
Exp. 1 Exp. 2
cpm
Exp. 1 Exp. 2
U/ml
1 - - 4,062 ± 587 3,529 ± 412 0.25 0.25
+ - 18,443 t 1,729 15,854 t 918 1.75 1.50
+ + 884 ± 312 991 ± 189 - -
- + 419 ± 98 387 ± 121 - -
0.5 - - 2,144 t 648 1,927 ± 344 0.20 0.10
+ - 16,876 t 1,385 17,442 ± 995 1.50 1.75
+ + 745 1 227 689 ± 212 - -
- + 527 ± 101 581 ± 97 - -
Allogeneic tumor cells
1 + - 4,289 ± 491 3,495 ± 367 0.25 0.20
+ + 927 ± 115 789 ± 298 - -
0.5 + - 2,629 t 881 2,123 t 515 0.20 0.10
+ + 825 ± 191 754 ± 253 - -
Medium alone - - 507 t 103 485 ± 105
+ - 689 ± 81 546 t 75COZZOLINO ET AL.
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activated by malignant cells in vivo. Alternatively, the OKM1-, Leu-7- cell
suspension could contain contaminant malignant cells capable of providing the
appropriate antigenic stimulus.
Discussion
The present study demonstrates that lymph nodes that drain the tumor site
contain cells capable of responding to the malignant cells in vitro. These cells
have specificity for autologous but not for allogeneic neoplastic cells, as shown
by the tests with a panel ofallogeneic malignant cells, and could be detected in
a proliferative assay only if two conditions were met: (a) exogenous IL-2 must be
supplied to sustain the proliferation initiated by coculture with tumor cells, and
(b) suppressor cells must be removed. Superimposable results were obtained with
two different tumor types, a finding that could suggest a common pattern of
immune response shared by different neoplasias.
Infiltrated lymph nodes contained lymphocytes with a T3+, T8+, OKM1+,
Leu-7+ surface phenotype that suppressed the response to the malignant cells.
The suppressive capacities of T3+, T8+, OKM1+, Leu-7+ lymphocytes were
confirmed by the observation that readdition of such cells to the OKM1-, Leu-
7- cell suspensions inhibited the response to tumor cells. Suppressor cells have
been reported both in mice and humans with malignancies, although different
experimental systems have generally been used to detect them (10, 31-34). The
mode of action of the suppressor cells described here, together with a character-
ization of their properties, will be the subject ofa separate study.2 However, it is
worth mentioning that the suppression appears to be specific for the response to
tumor cells, and is not merely caused by IL-2 consumption by OKM1+, Leu-7+
cells.
Noninvaded lymph nodes contained neither cells responding to the malignant
cells nor suppressor cells. These findings may suggest that cells which respond
to the malignant cells remain entrapped in the metastatic lymph nodes and do
not recirculate.
The present studies were focused on the mechanisms involved in the stimula-
tion of the cells responding to tumor cells. Coculture with autologous tumor
cells induced the expression of IL-2 receptors. This step, however, was not
followed by cell proliferation because oflack ofIL-2 production in the cultures.
Recent work on the multistep process ofTcell triggering has shown that resting
(or memory) and proliferating T lymphocytes require different signals in order
to progress through the cell cycle (28, 29, 35-37). In particular, unlike prolif-
erating cells, resting T lymphocytes require, in addition to the presence of
antigen, a signal delivered by IL-1 (28, 29, 38). It is still debated whether or not
this signal is necessary for the subsequent expression of IL-2 receptors (39, 40),
or whether it induces the production of IL-2 (28, 29). The present data are in
agreement with the latter hypothesis . In the absence of detectable IL-1, T cells
expressed IL-2 receptors after antigen stimulation, but began to produce IL-2
only after the addition ofexogenous IL-1. While the absence ofIL-1 production
s Cozzolino, F., M. Torcia, A. M. Carossino, R. Giordani, C. Selli, G. Talini, E. Reali, A. Novelli,
V. Pistoia, and M. Ferrarini. Functional analysis of suppressor cells from regional lymph nodes of
cancer patients. Manuscript in preparation.314
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explains the failure ofT cells to produce IL-2 in the MLTC, there are no clear
explanations for the lack of IL-1 production after stimulation with malignant
cells. One possible interpretation could be that macrophages or other accessory
cells committed to IL-1 production are not induced to do so solely by the
presence of (or encounter with) neoplastic cells. An alternative and not mutually
exclusive explanation may be that T cells have to activate accessory cells to
release IL-1 . This activation may be mediated, for example, through the pro-
duction ofIFN-7 (41, 42). The recognition oftumor cells may not be a sufficient
signal for inducing the release of this lymphokine. The possibility also exists that
macrophages from the metastatic lymph nodes have an impaired capacity of
producing IL-1, as reported in other experimental systems (43). Finally, the
possible presence of IL-1 inhibitors has to be considered (44). All of the above
hypotheses are compatible with the observation that OKM1-, Leu-7- cells
respond to PHA. The response to this mitogen is less dependent on accessory
cells, and PHA per se induces abundant IL-1 release by macrophages (45).
The short-term lines derived from the cells responding to tumor cells required
theconstant presence of IL-2 for antigen-induced proliferation. This observation
raises the question of whether or not they represent a special T cell subset.
However, so far, the surface marker analysis has not revealed particular differ-
ences between cells responding to tumor cells and those directed to other types
of antigen. Furthermore, cells that are dependent on constant stimulation with
both antigen and IL-2 for growth have been described also in different experi-
mental systems (46-49).
T cells isolated from lymph nodes were not cytotoxic for the malignant cells
when tested immediately after isolation. Cytotoxic T cells were, however, de-
tected in one ofthe cell lines obtained. The availability of this cell line provided
a further opportunity for testing both the antigen specificity and the restriction
of the responding cells. Again, these cells were induced to proliferate only by
the autologous malignant cells. Furthermore, their proliferative response was
inhibited by an anti-HLA-A,B,C mAb, as could be expected for class I-restricted
cytolytic T cells. Finally, the lytic activity was exerted only and specifically on
the autologous malignant targets. Taken together, these data indicate that lymph
nodes from patients with malignancies contain cytotoxic T cell precursors, which
may be usable in novel therapeutical approaches.
Summary
The specific immune response against the malignant cells was investigated in
patients with urinary bladder or larynx cancer. Lymphocytes from lymph nodes
that drain the tumor site were tested for their proliferative and cytotoxic
capacities against autologous malignant cells isolated from the primary tumor.
In no occasion was a proliferative or a cytotoxic response observed. However,
when the lymph node cell suspensions were depleted of cells expressing both
OKM1 and Leu-7 markers by rosetting with the appropriate mAbs, a prolifera-
tive response could be observed . The lymphocytes responded to autologous
tumor cells only if IL-2 was added to the cultures. IL-2 alone induced some cell
proliferation, which was not, however, comparable to that observed in response
to both IL-2 and tumor cells. A panel ofallogeneic tumor cells consistently failedCOZZOLINO ET AL.
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to stimulate OKM1-, Leu-7- cells in vitro. Response to autologous tumor cells
was not caused by HLA-encoded molecules, as occurs in the autologous mixed
lymphocyte reaction, since OKM 1 -, Leu-7- cells failed to be stimulated by
autologous non-T cells. A proliferative response was observed only with cells
from lymph nodes that had been classified as invaded by malignant cells according
to histopathologic criteria. Cells from noninvaded lymph nodes consistently failed
to respond.
Cells stimulated with autologous tumor cells could be expanded in short-term
lines by continuous addition of IL-2 and malignant cells. One of these lines,
which comprised mainly T8+ cells, was stimulated to proliferate only by autolo-
gous tumor cells, and its proliferative response was inhibitable by anti-class I
and not by anti-class II mAbs. This line showed lytic capacities against autologous
malignant targets, while it was inefficient against all of the other allogeneic cells
tested.
In another set of experiments, the mechanisms whereby exogenous IL-2 had
to be added to the cultures to sustain a proliferative response against neoplastic
cells were investigated. When cocultured with autologous malignant cells,
OKM1- , Leu-7- lymphocytes expressed IL-2 receptors, as could be assessed by
anti-Tac fluorescent staining. Under these culture conditions, these cells did not
produce IL-2, and no proliferation was observed. Addition of purified IL-1 to
the cultures induced IL-2 production and cell proliferation.
It is concluded that metastatic lymph nodes contain a T cell population that
can be detected in a proliferative assay when both suppressor cells are removed
and the appropriate molecular signals are supplied.
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